US Stocks Movement: Xeris Biopharma Surges on September 29 as XP-8121 Phase III Advances and Revenue Grows

Xeris Biopharma September 29 Surge Interpretation

Keywords: XP-8121 Phase III Progress, Revenue Growth

1. On September 9, the company stated at the XP-8121 project webinar that the phase III registration study is planned to commence by the end of 2026, with main results expected to be released in the second half of 2028 and approval and market launch by the U.S. Food and Drug Administration anticipated in 2030; the product's peak net revenue potential is projected at $1 billion to $3 billion.

2. On August 6, the company announced total revenue of $92.1 million for the second quarter of 2026, an increase of 29% year-over-year; net product revenue was $91 million, up 34% year-over-year, with Recorlev net revenue at $56.8 million, representing an 81% increase year-over-year. The company narrowed its full-year 2026 total revenue guidance to a range of $385 million to $390 million.

(Disclaimer: This content is generated by AI technology which collects and summarizes publicly available information. It is for reference only and does not constitute investment advice.)